CytoMed Therapeutics Ltd. Files January 2025 6-K Report

Ticker: GDTC · Form: 6-K · Filed: Jan 6, 2025 · CIK: 1873093

Cytomed Therapeutics LTD 6-K Filing Summary
FieldDetail
CompanyCytomed Therapeutics LTD (GDTC)
Form Type6-K
Filed DateJan 6, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, corporate-update

TL;DR

CytoMed Therapeutics filed a 6-K on Jan 6, 2025, updating its status as a foreign private issuer.

AI Summary

On January 6, 2025, CytoMed Therapeutics Limited announced its financial results for the period ending December 31, 2024. The company, formerly known as CytoMed Therapeutics Pte. Ltd., is a pharmaceutical preparations company based in Singapore.

Why It Matters

This filing provides an update on CytoMed Therapeutics' corporate activities and financial reporting as a foreign private issuer, offering insights into its operational status for investors.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

This Form 6-K is a report of a foreign private issuer filed for the month of January 2025, providing information to the SEC.

When was CytoMed Therapeutics Limited incorporated or previously named?

The company was formerly known as CytoMed Therapeutics Pte. Ltd., with a date of name change on July 16, 2021.

What is CytoMed Therapeutics Limited's principal executive office address?

The principal executive office is located at 1 Commonwealth Lane #08-22, Singapore 149544.

Does CytoMed Therapeutics file annual reports under Form 20-F or 40-F?

Yes, the company indicates it files annual reports under cover of Form 20-F.

What is the Standard Industrial Classification (SIC) code for CytoMed Therapeutics?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 17.7 · Accepted 2025-01-06 07:40:51

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: January 6, 2025 By: /s/ CHOO Chee Kong CHOO Chee Kong Director and Chairman

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing